The BINSA Act would add biotechnology to the technologies covered by outbound investment screening under the Defense Production Act. It defines biotechnology to include pharmaceutical and biological products, therapeutic compounds, drug discovery, clinical research and development, biologics manufacturing, and related intellectual property and know-how. The Treasury Secretary would issue rules defining the scope within one year, while excluding agricultural biotechnology, unrelated industrial fermentation, and basic academic research without a direct therapeutic or pharmaceutical use. The bill would also make licensing prohibited technology from a covered foreign person a prohibited transaction. It directs the Defense Secretary to report within 60 days on whether U.S. capital flowing into China’s biotechnology sector affects national security and military readiness.
The bill focuses on certain investments and technology transfers involving covered foreign persons. It does not describe a direct change to services or requirements for individuals. The Treasury Secretary would define the biotechnology rules after consulting other officials.
No publicly available information. The bill does not specify costs or funding.
The bill’s findings say that U.S. investment and technology transfers to Chinese biotechnology firms could increase strategic dependence and affect national security. They argue that biotechnology should be included in investment screening.
No publicly available information.